Lv1
40 积分 2024-06-18 加入
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
3个月前
已完结
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
3个月前
已完结
Double Primary Malignancies Involving Cutaneous Carcinoma
4个月前
已完结
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
4个月前
已完结
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
7个月前
已完结
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors
7个月前
已完结
Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα
8个月前
已完结
PI3K isoforms in cell signalling and vesicle trafficking
8个月前
已完结
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
8个月前
已完结
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
8个月前
已完结
皖公网安备34019202002308
